#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14856	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2014	727.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1355	1355	C	909	C	847	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14856	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2014	727.9	0	HET	.	.	.	C207T	.	207	207	C	378	378	C	852	C,T	648,140	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14856	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2014	727.9	0	HET	.	.	.	C451T	.	451	451	C	622	622	C	838	C,T	401,385	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26902	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3586	747.5	0	.	n	.	0	T695C	SNP	695	695	T	1047	1047	C	821	C,T,A	765,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26902	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3586	747.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2323	2323	C	879	C	814	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26902	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3586	747.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2397	2397	A	846	A	798	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26902	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3586	747.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2949	2949	C	851	C,T	789,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1770	folP	855	855	100.0	folP.l6.c30.ctg.1	1547	114.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1032	1034	AGC	172;172;172	A;G;C	162;163;161	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5020	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3475	144.2	1	SNP	p	S91F	1	.	.	271	273	TTC	601	603	TTC	163;166;167	T;T,C;C	151;155,1;156	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5020	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3475	144.2	1	SNP	p	D95G	1	.	.	283	285	GGC	613	615	GGC	163;160;162	G,A;G,A;C,T	153,1;148,2;150,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5020	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3475	144.2	1	SNP	p	G95N	0	.	.	283	285	GGC	613	615	GGC	163;160;162	G,A;G,A;C,T	153,1;148,2;150,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1502	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1359	110.0	1	SNP	p	G45D	0	.	.	133	135	GGC	564	566	GGC	185;186;186	G;G,A;C	171;171,1;175	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	750	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1023	72.5	0	.	n	.	0	A197.	DEL	197	197	A	579	579	A	159	A,G	149,1	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5598	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2880	193.6	1	SNP	p	D86N	0	.	.	256	258	GAC	522	524	GAC	198;199;198	G;A;C	191;190;190	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5598	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2880	193.6	1	SNP	p	R87W	0	.	.	259	261	CGT	525	527	CGT	202;202;202	C,A;G;T	192,1;194;191	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5598	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2880	193.6	1	SNP	p	R87I	0	.	.	259	261	CGT	525	527	CGT	202;202;202	C,A;G;T	192,1;194;191	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5598	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2880	193.6	1	SNP	p	S87R	1	.	.	259	261	CGT	525	527	CGT	202;202;202	C,A;G;T	192,1;194;191	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5598	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2880	193.6	1	SNP	p	S88P	0	.	.	262	264	TCC	528	530	TCC	202;201;201	T;C;C	193;189;191	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3908	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2833	137.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1695	1697	GGC	189;190;189	G;G;C	175;175;174	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1259	1261	GCC	212;215;213	G;C;C,A	194;192;192,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1262	1264	ATG	214;215;215	A;T;G,C	197;196;197,1	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1274	1276	ACC	209;208;208	A,G;C,T;C,G	187,1;189,1;188,1	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1274	1276	ACC	209;208;208	A,G;C,T;C,G	187,1;189,1;188,1	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1775	1777	ACC	204;201;204	A;C;C	187;188;194	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1829	1831	GCG	221;221;221	G;C;G	204;204;203	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1829	1831	GCG	221;221;221	G;C;G	204;204;203	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1952	1954	GGT	191;187;186	G;G;T	172;169;165	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1961	1963	AGC	173;169;168	A;G;C,T	157;155;153,1	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3770	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2336	160.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1979	1981	CCG	155;158;156	C,G;C,G;G	129,5;129,2;128	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5710	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3039	187.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1586	1588	CCG	192;192;196	C,T;C;G	172,1;176;175	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2376	porA	1146	1146	99.91	porA.l6.c30.ctg.1	1769	133.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	570	570	C	175	C	156	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	S271T	NONSYN	811	813	TCG	52	54	ACT	44;42;40	A;C;T	31;31;31	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	58	60	GAT	34;34;34	G;A;T	31;30;31	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	D276N	NONSYN	826	828	GAT	67	69	AAC	34;35;35	A;A;C	31;31;31	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	N277H	NONSYN	829	831	AAC	70	72	CAC	37;37;37	C;A;C	32;32;32	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	R307E	NONSYN	919	921	AGA	160	162	GAA	12;12;12	G;A;A	12;12;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	T311A	NONSYN	931	933	ACA	172	174	GCA	10;10;12	G;C;A	10;10;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	E312D	NONSYN	934	936	GAA	175	177	GAC	12;12;12	G;A;C	11;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	F314I	NONSYN	940	942	TTC	181	183	ATC	12;12;12	A;T;C	12;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	A316S	NONSYN	946	948	GCG	187	189	TCG	12;11;10	T;C;G	11;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	V318A	NONSYN	952	954	GTC	193	195	GCC	10;9;9	G;C;C	10;9;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	G319S	NONSYN	955	957	GGC	196	198	AGC	9;9;9	A;G;C	9;9;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	G320A	NONSYN	958	960	GGT	199	201	GCC	9;8;7	G;C;C	8;8;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	266	porB1a	984	222	90.99	porB1a.l15.c30.ctg.2	289	21.4	0	.	p	.	0	G322V	NONSYN	964	966	GGT	205	207	GTT	6;6;6	G;T;T	6;6;6	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2926	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1457	198.8	1	SNP	p	G120K	1	.	.	358	360	AAG	650	652	AAG	206;203;204	A;A;G	192;192;189	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2926	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1457	198.8	1	SNP	p	A121N	1	.	.	361	363	AAC	653	655	AAC	203;202;203	A;A;C	190;192;190	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2926	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1457	198.8	1	SNP	p	N121D	0	.	.	361	363	AAC	653	655	AAC	203;202;203	A;A;C	190;192;190	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10924	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	4919	221.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1202	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1092	109.3	1	SNP	p	V57M	1	.	.	169	171	ATG	450	452	ATG	230;232;235	A;T;G	222;225;229	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
